1
|
Liu C, Wang W, Feng J, Beno B, Raja T, Swidorski J, Manepalli RKVLP, Vetrichelvan M, Rao Jalagam P, Nair SK, Gupta A, Panda M, Ghosh K, Kaushikkumar Shukla J, Sale H, Shah D, Singh Gautam S, Patel D, Mathur A, Ellsworth BA, Cheng D, Regueiro-Ren A. Identification of benzothiazole derived monosaccharides as potent, selective, and orally bioavailable inhibitors of human and mouse galectin-3; a rare example of using a S···O binding interaction for drug design. Bioorg Med Chem 2024; 101:117638. [PMID: 38394996 DOI: 10.1016/j.bmc.2024.117638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2023] [Revised: 02/07/2024] [Accepted: 02/09/2024] [Indexed: 02/25/2024]
Abstract
As a result of our continued efforts to pursue Gal-3 inhibitors that could be used to fully evaluate the potential of Gal-3 as a therapeutic target, two novel series of benzothiazole derived monosaccharides as potent (against both human and mouse Gal-3) and orally bioavailable Gal-3 inhibitors, represented by 4 and 5, respectively, were identified. These discoveries were made based on proposals that the benzothiazole sulfur atom could interact with the carbonyl oxygen of G182/G196 in h/mGal-3, and that the anomeric triazole moiety could be modified into an N-methyl carboxamide functionality. The interaction between the benzothiazole sulfur and the carbonyl oxygen of G196 in mGal-3 was confirmed by an X-ray co-crystal structure of early lead 9, providing a rare example of using a S···O binding interaction for drug design. It was found that for both the series, methylation of 3-OH in the monosaccharides caused no loss in h & mGal-3 potencies but significantly improved permeability of the molecules.
Collapse
Affiliation(s)
- Chunjian Liu
- Research & Early Development, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543, United States.
| | - Wei Wang
- Research & Early Development, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543, United States
| | - Jianxin Feng
- Research & Early Development, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543, United States
| | - Brett Beno
- Research & Early Development, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543, United States
| | - Thiruvenkadam Raja
- Biocon-Bristol Myers Squibb Research and Development Center, Bangalore 560099, India
| | - Jacob Swidorski
- Research & Early Development, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543, United States
| | | | | | - Prasada Rao Jalagam
- Biocon-Bristol Myers Squibb Research and Development Center, Bangalore 560099, India
| | - Satheesh K Nair
- Biocon-Bristol Myers Squibb Research and Development Center, Bangalore 560099, India
| | - Anuradha Gupta
- Biocon-Bristol Myers Squibb Research and Development Center, Bangalore 560099, India
| | - Manoranjan Panda
- Biocon-Bristol Myers Squibb Research and Development Center, Bangalore 560099, India
| | - Kaushik Ghosh
- Biocon-Bristol Myers Squibb Research and Development Center, Bangalore 560099, India
| | | | - Harinath Sale
- Biocon-Bristol Myers Squibb Research and Development Center, Bangalore 560099, India
| | - Devang Shah
- Biocon-Bristol Myers Squibb Research and Development Center, Bangalore 560099, India
| | | | - Dipal Patel
- Research & Early Development, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543, United States
| | - Arvind Mathur
- Research & Early Development, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543, United States
| | - Bruce A Ellsworth
- Research & Early Development, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543, United States
| | - Dong Cheng
- Research & Early Development, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543, United States
| | - Alicia Regueiro-Ren
- Research & Early Development, Bristol Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543, United States
| |
Collapse
|
2
|
Multicomponent reaction derived small di- and tri-carbohydrate-based glycomimetics as tools for probing lectin specificity. Glycoconj J 2022; 39:587-597. [PMID: 36001188 DOI: 10.1007/s10719-022-10079-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2022] [Revised: 07/14/2022] [Accepted: 08/10/2022] [Indexed: 11/04/2022]
Abstract
Lectins, carbohydrate-binding proteins, play important functions in all forms of life from bacteria and viruses to plants, animals, and humans, participating in cell-cell communication and pathogen binding. In an attempt to modify lectin functions, artificial lectin ligands were made usually as big dendrimeric or cluster multivalent glycomimetic structures. Here we synthesized a novel set of glycomimetic ligands through protection/deprotection multicomponent reactions (MCR) approach. Multivalent di-and tri-carbohydrate glycomimetics containing D-fructose, D-galactose, and D-allose moieties were prepared in 63-96% yield. MCR glycomimetics demonstrated different binding abilities for plant lectins Con A and UEA I, and human galectin-3. Information gained about the influence of molecule structure, multivalency and optical purity on the lectin binding ability can be used in lectin detection and sensitivity measurements to further facilitate understanding of carbohydrate recognition process.
Collapse
|